Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells

Table 1 Cytotoxicity of BTZ, Ara-C and DSF/Cu²⁺ in AML cell lines

Cell lines	AML Classification	Age	Type	IC₅₀ (nM) (Mean ± SD)
Cell lines	AML Classification	Age	Type	BTZ	Ara-C	DSF/Cu²⁺
CMK	Acute Megakaryoblastic Leukemia	10 months	Down Syndrome Relapse	4.9 ± 2.6	70 ± 30	105 ± 25
CMY	Acute Megakaryoblastic Leukemia	21 months	Down SyndromeRefractory	2.6 ± 0.6	1795 ± 391	72 ± 16
CMS	Acute Megakaryoblastic Leukemia	2 years		4.3 ± 1.6	154 ± 21	82 ± 4.7
THP-1	Acute Monocytic Leukemia MLL-AF9	1 year	Relapse	7.8 ± 3.3	3537 ± 331	79 ± 18
M-07e	Acute Megakaryoblastic Leukemia	1 year		3.7 ± 0.8	24 ± 4.4	68 ± 22
AML-193	Acute Monocytic Leukemia	13 years	Relapse	4.6 ± 3.1	414 ± 29.9	53 ± 12.7
Kasumi-1	AML t(8,21)	7 years	2nd relapse after BMT	6.7 ± 3.0	27.6 ± 2.5	89 ± 13
Molm-13	AML with Flt-3 ITD	20 years	Relapse	6.8 ± 3.6	4 ± 1	98 ± 10
MV-4-11	Biphenotypic Myelomonocytic Leukemia FLT-3 ITD	10 years		3.4 ± 0.5	278 ± 73	50 ± 10
NB4	Acute Promyelocytic Leukemia	20 years	Relapse	2.7 ± 1.4	123 ± 114	57 ± 5
HL-60	Acute Promyelocytic Leukemia	36 years		7.1 ± 1.5	424 ± 172	67 ± 19
KG-1a	Acute Myeloid leukemia	59 years		17.0 ± 0.9	177 ± 43	79 ± 11
TF-1	Erythroleukemia	35 years		8.3 ± 2.1	75 ± 52	101 ± 21
HEL 92.1.7	Erythroleukemia	30 years		6.2 ± 2.9	102 ± 13	100 ± 8.5

IC₅₀ values are presented as mean ± standard deviation. Data represent at least three replicate experiments. Ara-C cytarabine, BTZ bortezomib, DSF disulfiram

ISSN: 1756-9966